|ASH 2018 Annual Meeting Highlights in Multiple Myeloma|
CME, CPE, CNE
Faith Davies, MD, MBBCh, MRCP, FRCPath; Meletios A. Dimopoulos, MD; Shaji K. Kumar, MD; María-Victoria Mateos, MD, PhD; Philip L. McCarthy, MD; Noopur Raje, MD; Dan T. Vogl, MD, MSCE
|Release Date: December 21, 2018|
Expiration Date: December 21, 2019
In this activity, key opinion leaders present important highlights of several significant scientific updates in multiple myeloma (MM) presented at the 2018 American Society of Hematology (ASH) Annual Meeting. In this activity, you can view videos from the meeting and listen as they share their insights on a variety of abstracts covering topics including, but not limited to: the impact of early vs. late relapse in response to carfilzomib; novel treatment options for penta-refractory MM; CAR T-cell therapy; once-weekly vs. twice-weekly carfilzomib plus dexamethasone; venetoclax plus carfilzomib and dexamethasone in patients with RRMM; and maintenance therapy with ixazomib.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Bristol-Myers Squibb, Celgene Corporation, Takeda Oncology
|Begin, Earn CreditView Only, No Credit|